Researchers study possible HIV cure; Kythera touts success of chin-fat therapy in Ph2; Sunesis wins fast-track designation;

@FierceBiotech: FDA chief vows fast delivery of new biosimilar rules. Report | Follow @FierceBiotech

@JohnCFierce: So, how about it scribes? Is Vertex the smartest drug developer out there? | Follow @JohnCFierce 

> A team of investigators are mounting a small human study to see if Antabuse, a drug used for alcohol abuse, can rid HIV patients of the last remnants of the virus that linger following treatment. Story

> Los Angeles-based Kythera Biopharmaceuticals says a third mid-stage study of ATX-101, designed to eliminate fat under the chin, has posted positive data. "The results from this study are exciting and indicate the potential of ATX-101 as an effective and well-characterized treatment for the aesthetic reduction of small volumes of fat," said Joel Schlessinger, MD, a cosmetic surgeon and an investigator in this study. Release

> Sunesis Pharmaceuticals announced that its lead drug, vosaroxin, has been granted Fast Track designation by the FDA for the potential treatment of relapsed or refractory acute myeloid leukemia in combination with cytarabine. Release

> Caraco Pharmaceutical Laboratories in Detroit will merge with India's Sun Pharmaceutical, its majority owner. Story

And Finally... It may seem paradoxical, but being part of a crowd is what makes you unique, according to UCLA life scientists. Release